Skip to main content

Advertisement

SpringerLink
Log in

Sorafenib combined with transarterial chemoembolization in patients with hepatocellular carcinoma: a meta-analysis and systematic review

  • Original Article
  • Published:
Hepatology International Aims and scope Submit manuscript

Abstract

Purpose

Combination therapy of sorafenib and transarterial chemoembolization (TACE) has shown benefits in treating advanced hepatocellular carcinoma (HCC). This study evaluated the efficacy and safety of TACE + sorafenib.

Methods

MEDLINE, the Cochrane Library, EMBASE, and the ISI Web of Knowledge were searched (until 31 December 2013) for studies comparing TACE and TACE + sorafenib in treating patients with advanced HCC. Sensitivity and quality assessments were performed.

Results

Five comparative studies (2 were randomized control trials) that included 899 patients were used in the meta-analysis. Patients treated with TACE + sorafenib had better prognoses in terms of time to progression (TTP) compared to those with TACE + placebo or TACE alone; hazard ratios (HRs) ranged from 0.40 to 0.87, with the combined HR 0.61 (95 % CI 0.39–0.95, p = 0.031). However, the combined HR for overall survival (OS) did not differ significantly between patients treated with TACE + sorafenib and those with TACE + placebo or TACE alone (combined HR = 0.79, 95 % CI = 0.54–1.16, p = 0.235). Sensitivity analysis indicated the findings for TTP may be overly influenced by at least one of the studies.

Conclusions

In summary, our meta-analysis found that TACE + sorafenib can improve TTP. We did not find the combined therapy improved OS. Additional randomized controlled studies are necessary to further investigate the clinical benefit of TACE + sorafenib in treating advanced HCC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Waller LP, Deshpande V, Pyrsopoulos N. Hepatocellular carcinoma: a comprehensive review. World J Hepatol. 2015;7:2648–63.

  2. Chang MH. Prevention of hepatitis B virus infection and liver cancer. Recent Results Cancer Res. 2014;193:75–95.

    Article  CAS  PubMed  Google Scholar 

  3. Lencioni R, Chen XP, Dagher L, Venook AP. Treatment of intermediate/advanced hepatocellular carcinoma in the clinic: how can outcomes be improved? Oncologist. 2010;15(Suppl 4):42–52.

    Article  CAS  PubMed  Google Scholar 

  4. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007;132:2557–2576.

    Article  CAS  PubMed  Google Scholar 

  5. Forner A, Reig ME, de Lope CR, Bruix J. Current strategy for staging and treatment: the BCLC update and future prospects. Semin Liver Dis. 2010;30:61–74.

    Article  CAS  PubMed  Google Scholar 

  6. Minagawa M, Makuuchi M. Treatment of hepatocellular carcinoma accompanied by portal vein tumor thrombus. World J Gastroenterol. 2006;12:7561–7567.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Chuan-Xing L, Xu H, Bao-Shan H, Yong L, Pei-Jian S, Xian-Yi Y, et al. Efficacy of therapy for hepatocellular carcinoma with portal vein tumor thrombus: chemoembolization and stent combined with iodine-125 seed. Cancer Biol Ther. 2011;12:865–71.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Kasai K, Ushio A, Kasai Y, Sawara K, Miyamoto Y, Oikawa K, et al. Combination therapy of intra-arterial 5-fluorouracil and systemic pegylated interferon alpha-2b for advanced hepatocellular carcinoma. Int J Clin Oncol. 2011;16:221–229.

    Article  CAS  PubMed  Google Scholar 

  9. Katamura Y, Aikata H, Takaki S, Azakami T, Kawaoka T, Waki K, et al. Intra-arterial 5-fluorouracil/interferon combination therapy for advanced hepatocellular carcinoma with or without three-dimensional conformal radiotherapy for portal vein tumor thrombosis. J Gastroenterol. 2009;44:492–502.

    Article  CAS  PubMed  Google Scholar 

  10. Uka K, Aikata H, Takaki S, Miki D, Jeong SC, Hiramatsu A, et al. Similar effects of recombinant interferon-alpha-2b and natural interferon-alpha when combined with intra-arterial 5-fluorouracil for the treatment of advanced hepatocellular carcinoma. Liver Int. 2007;27:1209–1216.

    CAS  PubMed  Google Scholar 

  11. Zhang XB, Wang JH, Yan ZP, Qian S, Du SS, Zeng ZC. Hepatocellular carcinoma with main portal vein tumor thrombus: treatment with 3-dimensional conformal radiotherapy after portal vein stenting and transarterial chemoembolization. Cancer. 2009;115:1245–1252.

    Article  PubMed  Google Scholar 

  12. Lin CS, Jen YM, Chiu SY, Hwang JM, Chao HL, Lin HY, et al. Treatment of portal vein tumor thrombosis of hepatoma patients with either stereotactic radiotherapy or three-dimensional conformal radiotherapy. Jpn J Clin Oncol. 2006;36:212–217.

    Article  PubMed  Google Scholar 

  13. Marelli L, Stigliano R, Triantos C, Senzolo M, Cholongitas E, Davies N, et al. Treatment outcomes for hepatocellular carcinoma using chemoembolization in combination with other therapies. Cancer Treat Rev. 2006;32:594–606.

    Article  CAS  PubMed  Google Scholar 

  14. Llovet JM, Real MI, Montaña X, Planas R, Coll S, Aponte J, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet. 2002;359:1734–1739.

    Article  PubMed  Google Scholar 

  15. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology. 2003;37:429–442.

    Article  CAS  PubMed  Google Scholar 

  16. Li X, Feng GS, Zheng CS, Zhuo CK, Liu X. Expression of plasma vascular endothelial growth factor in patients with hepatocellular carcinoma and effect of transcatheter arterial chemoembolization therapy on plasma vascular endothelial growth factor level. World J Gastroenterol. 2004;10:2878–2882.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature. 2000;407:249–257.

    Article  CAS  PubMed  Google Scholar 

  18. Sergio A, Cristofori C, Cardin R, Pivetta G, Ragazzi R, Baldan A, et al. Transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): the role of angiogenesis and invasiveness. Am J Gastroenterol. 2008;103:914–921.

    Article  PubMed  Google Scholar 

  19. Nexavar (sorafenib). 2010; available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021923s008s009lbl.pdf.

  20. Strebel BM, Dufour JF. Combined approach to hepatocellular carcinoma: a new treatment concept for nonresectable disease. Expert Rev Anticancer Ther. 2008;8:1743–1749.

    Article  CAS  PubMed  Google Scholar 

  21. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med. 2009;151:W65–W94.

    Article  PubMed  Google Scholar 

  22. Sweeting MJ, Sutton AJ, Lambert PC. What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data. Stat Med. 2004;15;23(9):1351–1375.

  23. Hardy RJ, Thompson SG. Detecting and describing heterogeneity in meta-analysis. Stat Med. 1998 30;17(8):841–856.

  24. Takkouche B, Cadarso-Suarez C, Spiegelman D. Evaluation of old and new tests of heterogeneity in epidemiologic meta-analysis. Am J Epidemiol. 1999;150:206–215.

    Article  CAS  PubMed  Google Scholar 

  25. National Research Council. Combing Information: Statistical Issues and Opportunities for Research. Washington, DC: National Academy Press; 1992.

    Google Scholar 

  26. Qu XD, Chen CS, Wang JH, Yan ZP, Chen JM, Gong GQ, et al. The efficacy of TACE combined sorafenib in advanced stages hepatocellullar carcinoma. BMC Cancer. 2012;12:263.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Kudo M, Imanaka K, Chida N, Nakachi K, Tak WY, Takayama T, et al. Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma. Eur J Cancer. 2011;47:2117–2127.

    Article  CAS  PubMed  Google Scholar 

  28. Sansonno D, Lauletta G, Russi S, Conteduca V, Sansonno L, Dammacco F. Transarterial chemoembolization plus sorafenib: a sequential therapeutic scheme for HCV-related intermediate-stage hepatocellular carcinoma: a randomized clinical trial. Oncologist. 2012;17:359–663.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Bai W, Wang YJ, Zhao Y, Qi XS, Yin ZX, He CY, et al. Sorafenib in combination with transarterial chemoembolization improves the survival of patients with unresectable hepatocellular carcinoma: a propensity score matching study. J Dig Dis. 2013;14:181–190.

    Article  CAS  PubMed  Google Scholar 

  30. Muhammad A, Dhamija M, Vidyarthi G, Amodeo D, Boyd W, et al. Comparative effectiveness of traditional chemoembolization with or without sorafenib for hepatocellular carcinoma. World J Hepatol. 2013;5:364–371.

    Article  PubMed  PubMed Central  Google Scholar 

  31. Common terminology criteria for adverse events. Available from: http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm.

  32. Liu L, Chen H, Wang M, Zhao Y, Cai G, Qi X, et al. Combination therapy of sorafenib and TACE for unresectable HCC: a systematic review and meta-analysis. PLoS One. 2014;9:e91124.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Fu QH, Zhang Q, Bai XL, Hu QD, Su W, Chen YW, et al. Sorafenib enhances effects of transarterial chemoembolization for hepatocellular carcinoma: a systematic review and meta-analysis. J Cancer Res Clin Oncol. 2014;140:1429–1440.

    Article  CAS  PubMed  Google Scholar 

  34. Zhang L, Hu P, Chen X, Bie P. Transarterial chemoembolization (TACE) plus sorafenib versus TACE for intermediate or advanced stage hepatocellular carcinoma: a meta-analysis. PLoS One. 2014;9:e100305.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Yang M, Yuan JQ, Bai M, Han GH. Transarterial chemoembolization combined with sorafenib for unresectable hepatocellular carcinoma: a systematic review and meta-analysis. Mol Biol Rep. 2014;41:6575–6582.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Digestive Internal Medicine, Gan Nan Medical University Pingxiang Hospital, 128 Guangchang Road, Pingxiang, 337055, Jiangxi, People’s Republic of China

    Guiliang Wang, Ping Qiu, Linfang Xu, Ping Wen & Jianbo Wen

  2. Department of Digestive Internal Medicine, 307 Hospital of PLA, Beijing, People’s Republic of China

    Guiliang Wang & Yan Liu

  3. Department of Pharmaceutical Sciences, College of Pharmacy, University of South Florida, Tampa, FL, 33612, USA

    Shu-feng Zhou

  4. Laboratory of Shock, Department of Pathophysiology, Xiangya School of Medicine, Central South University, Changsha, Hunan, 410008, People’s Republic of China

    Xianzhong Xiao

Authors
  1. Guiliang Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yan Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Shu-feng Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ping Qiu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Linfang Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ping Wen
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Jianbo Wen
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Xianzhong Xiao
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Xianzhong Xiao.

Ethics declarations

Funding

None.

Conflict of interest

Guiliang Wang, Yan Liu, Shu-feng Zhou, Ping Qiu, Linfang Xu, Ping Wen, Jianbo Wen, and Xianzhong Xiao declare that they have no conflict of interest.

Ethical approval

This article does not contain any studies with human participants or animals performed by any of the authors.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wang, G., Liu, Y., Zhou, Sf. et al. Sorafenib combined with transarterial chemoembolization in patients with hepatocellular carcinoma: a meta-analysis and systematic review. Hepatol Int 10, 501–510 (2016). https://doi.org/10.1007/s12072-015-9700-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12072-015-9700-7

Keywords

Search

Navigation